Literature DB >> 22937408

Atypical creutzfeldt-jakob disease evolution after electroconvulsive therapy for catatonic depression.

Iria Grande1, Juan Fortea, Ellen Gelpi, Itziar Flamarique, Marc Udina, Jordi Blanch, Raquel Sánchez-Valle.   

Abstract

We describe a case report of an 80-year-old woman who presented with symptomatology compatible with an episode of major depression with catatonia. After psychiatric admission, electroconvulsive therapy (ECT) was applied, but symptoms progressed with cognitive impairment, bradykinesia, widespread stiffness, postural tremor, and gait disturbance. After compatible magnetic resonance imaging (MRI), diffusion changes, and electroencephalogram (EEG) findings the case was reoriented to Creutzfeldt-Jakob disease (CJD). The genetic study found a methionine/valine heterozygosity at codon 129 of the prion protein gene PrP(Sc). On followup, a significant clinical recovery turned out. For this reason, EEG and MRI were repeated and confirmed the findings. The patient subsequently demonstrated progressive clinical deterioration and died 21 months later. The diagnosis was verified postmortem by neuropathology. The vCJD subtype MV2 is indeed characterized by early and prominent psychiatric symptoms and a prolonged disease duration however no frank clinical recovery has before been reported.

Entities:  

Year:  2011        PMID: 22937408      PMCID: PMC3420744          DOI: 10.1155/2011/791275

Source DB:  PubMed          Journal:  Case Rep Psychiatry        ISSN: 2090-6838


  11 in total

1.  The varied neuropsychiatric presentations of Creutzfeldt-Jakob disease.

Authors:  C K Moellentine; T A Rummans
Journal:  Psychosomatics       Date:  1999 May-Jun       Impact factor: 2.386

2.  First symptom in sporadic Creutzfeldt-Jakob disease.

Authors:  G D Rabinovici; P N Wang; J Levin; L Cook; M Pravdin; J Davis; S J DeArmond; N M Barbaro; J Martindale; B L Miller; M D Geschwind
Journal:  Neurology       Date:  2006-01-24       Impact factor: 9.910

3.  Clinical findings and diagnostic tests in the MV2 subtype of sporadic CJD.

Authors:  Anna Krasnianski; Walter J Schulz-Schaeffer; Kai Kallenberg; Bettina Meissner; Donald A Collie; Sigrun Roeber; Mario Bartl; Uta Heinemann; Daniela Varges; Hans A Kretzschmar; Inga Zerr
Journal:  Brain       Date:  2006-05-23       Impact factor: 13.501

4.  Diffusion weighted MRI in the early phase after electroconvulsive therapy.

Authors:  Kristina Szabo; Jochen G Hirsch; Martin Krause; Gabriele Ende; Fritz A Henn; Alexander Sartorius; Achim Gass
Journal:  Neurol Res       Date:  2007-04       Impact factor: 2.448

5.  Prevalence of depression among older Americans: the Aging, Demographics and Memory Study.

Authors:  David C Steffens; Gwenith G Fisher; Kenneth M Langa; Guy G Potter; Brenda L Plassman
Journal:  Int Psychogeriatr       Date:  2009-06-12       Impact factor: 3.878

6.  The cognitive effects of electroconvulsive therapy in community settings.

Authors:  Harold A Sackeim; Joan Prudic; Rice Fuller; John Keilp; Philip W Lavori; Mark Olfson
Journal:  Neuropsychopharmacology       Date:  2006-08-23       Impact factor: 7.853

Review 7.  Creutzfeldt-Jakob disease, new variant creutzfeldt-jakob disease, and bovine spongiform encephalopathy.

Authors:  C C Weihl; R P Roos
Journal:  Neurol Clin       Date:  1999-11       Impact factor: 3.806

8.  Diagnostic value of periodic complexes in Creutzfeldt-Jakob disease.

Authors:  Bernhard J Steinhoff; Inga Zerr; Maya Glatting; Walter Schulz-Schaeffer; Sigrid Poser; Hans A Kretzschmar
Journal:  Ann Neurol       Date:  2004-11       Impact factor: 10.422

9.  ECT in patients with psychopathology related to acute neurologic illness.

Authors:  Keith G Rasmussen; Dionne A Hart; Timothy W Lineberry
Journal:  Psychosomatics       Date:  2008 Jan-Feb       Impact factor: 2.386

10.  Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease.

Authors:  I Zerr; K Kallenberg; D M Summers; C Romero; A Taratuto; U Heinemann; M Breithaupt; D Varges; B Meissner; A Ladogana; M Schuur; S Haik; S J Collins; Gerard H Jansen; G B Stokin; J Pimentel; E Hewer; D Collie; P Smith; H Roberts; J P Brandel; C van Duijn; M Pocchiari; C Begue; P Cras; R G Will; P Sanchez-Juan
Journal:  Brain       Date:  2009-09-22       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.